ARLINGTON, VA (September 14, 2022) — Healthcare professionals should use antibiotics and diagnostic testing judiciously during the early stages of an epidemic, despite a strong desire to do something for patients when treatment options are limited, the Society for Healthcare Epidemiology of America said in a statement released today.
The statement follows a national report that found 80% of patients hospitalized in the first six months of the COVID-19 pandemic were prescribed antibiotics on admission even though they were rarely indicated at that point. Use of antibiotics in situations where they are not needed or beneficial leads to the growth of hard-to-treat resistant bacteria.
“The COVID-19 pandemic highlights the human desire of healthcare personnel to intervene, particularly when a patient is severely ill, which can lead to a suspension of evidence-based medicine at the bedside,” according to the SHEA Statement on Antibiotic Stewardship in Hospitals During Public Health Emergencies.
Uncertainty about the COVID-19 diagnosis was paired with a desire to help patients, concern about bacterial co-infections, and misleading results from a variety of diagnostic tests to contribute to the rise in overuse of antibiotics early in the pandemic, the statement said.
“The COVID-19 pandemic is ripe with lessons for future viral pandemics,” said Tamar Barlam, MD, lead author of the paper and chair of the SHEA Antimicrobial Stewardship Committee. “The overuse of antibiotics seen in the pandemic points to a need to strengthen antibiotic stewardship programs, so they are positioned to provide guidance across disciplines.
”The statement provides strategies for hospitals and healthcare personnel to improve antibiotic prescribing in the face of new infectious disease outbreaks. It describes circumstances when an antibiotic should be considered in a respiratory viral epidemic, and outlines situations where diagnostic tests are appropriate.
The guidance comes on the heels of a special report from the Centers for Disease Control and Prevention that concluded antimicrobial-resistant hospital-onset infections and deaths increased by at least 15% during the first year of the pandemic.
“These setbacks can and must be temporary,” CDC Director Rochelle Walensky, M.D., MPH, said in the foreword to the CDC report. “The COVID-19 pandemic has made it clear—prevention is preparedness. We must prepare our public health systems to fight multiple threats, simultaneously. Because antimicrobial resistance will not stop, we must meet the challenge."
The SHEA statement was published today in the organization’s journal Infection Control & Hospital Epidemiology.
Published through a partnership between the Society for Healthcare Epidemiology of America and Cambridge University Press, Infection Control & Hospital Epidemiology provides original, peer-reviewed scientific articles for anyone involved with an infection control or epidemiology program in a hospital or healthcare facility. ICHE is ranked 24th out of 94 Infectious Disease Journals in the latest Web of Knowledge Journal Citation Reports from Clarivate.
The Society for Healthcare Epidemiology of America (SHEA) is a professional society representing more than 2,000 physicians and other healthcare professionals around the world who possess expertise and passion for healthcare epidemiology, infection prevention, and antimicrobial stewardship. The society’s work improves public health by establishing infection-prevention measures and supporting antibiotic stewardship among healthcare providers, hospitals, and health systems. This is accomplished by leading research studies, translating research into clinical practice, developing evidence-based policies, optimizing antibiotic stewardship, and advancing the field of healthcare epidemiology. SHEA and its members strive to improve patient outcomes and create a safer, healthier future for all. Visit SHEA online at shea-online.org, facebook.com/SHEApreventingHAIs and twitter.com/SHEA_Epi.
Infection Control and Hospital Epidemiology
Method of Research
Subject of Research
SHEA Statement on Antibiotic Stewardship in Hospitals During Public Health Emergencies
Article Publication Date
S.S. reports an investigator-initiated Merck grant on cost-effectiveness of letermovir in hematopoietic stem cell transplant patients. G.F. reports a clinical study grant from Regeneron for inpatient monoclonal against SARS-CoV-2. All other authors report no conflicts of interest.